ProShare Advisors’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.77M Sell
7,788
-50
-0.6% -$8.9K ﹤0.01% 701
2026
Q1
$1.35M Sell
7,838
-2,918
-27% -$541K ﹤0.01% 737
2025
Q4
$2.15M Sell
10,756
-2,397
-18% -$435K ﹤0.01% 689
2025
Q3
$2.06M Buy
13,153
+4,386
+50% +$697K ﹤0.01% 693
2025
Q2
$1.33M Buy
8,767
+653
+8% +$87.1K ﹤0.01% 739
2025
Q1
$1.22M Sell
8,114
-5,425
-40% -$910K ﹤0.01% 759
2024
Q4
$2.5M Sell
13,539
-24
-0.2% -$4.62K 0.01% 653
2024
Q3
$2.67M Buy
13,563
+3,588
+36% +$746K 0.01% 634
2024
Q2
$2.06M Buy
9,975
+583
+6% +$132K 0.01% 665
2024
Q1
$2.54M Sell
9,392
-2,105
-18% -$503K 0.01% 633
2023
Q4
$2.72M Sell
11,497
-597
-5% -$117K 0.01% 606
2023
Q3
$2.37M Sell
12,094
-746
-6% -$153K 0.01% 623
2023
Q2
$2.7M Buy
12,840
+1,731
+16% +$344K 0.01% 622
2023
Q1
$2.24M Buy
11,109
+3,470
+45% +$786K 0.01% 643
2022
Q4
$1.66M Buy
7,639
+733
+11% +$160K 0.01% 649
2022
Q3
$1.36M Sell
6,906
-811
-11% -$175K 0.01% 681
2022
Q2
$1.65M Sell
7,717
-2,948
-28% -$720K 0.01% 676
2022
Q1
$3.03M Sell
10,665
-303
-3% -$93.4K 0.01% 638
2021
Q4
$4.13M Buy
10,968
+2,481
+29% +$964K 0.01% 611
2021
Q3
$3.5M Sell
8,487
-172
-2% -$71.4K 0.01% 587
2021
Q2
$3.2M Buy
8,659
+3,893
+82% +$1.3M 0.01% 604
2021
Q1
$1.38M Sell
4,766
-29
-0.6% -$8.06K ﹤0.01% 832
2020
Q4
$1.2M Buy
4,795
+580
+14% +$138K ﹤0.01% 801
2020
Q3
$954K Buy
4,215
+136
+3% +$28.2K ﹤0.01% 733
2020
Q2
$711K Buy
4,079
+1,391
+52% +$222K ﹤0.01% 804
2020
Q1
$339K Sell
2,688
-2,624
-49% -$394K ﹤0.01% 842
2019
Q4
$811K Buy
5,312
+487
+10% +$67.4K ﹤0.01% 870
2019
Q3
$639K Sell
4,825
-240
-5% -$32.2K ﹤0.01% 900
2019
Q2
$719K Sell
5,065
-861
-15% -$117K ﹤0.01% 883
2019
Q1
$861K Buy
5,926
+1,321
+29% +$174K 0.01% 832
2018
Q4
$521K Sell
4,605
-1,057
-19% -$132K ﹤0.01% 932
2018
Q3
$762K Buy
5,662
+443
+8% +$54.7K 0.01% 939
2018
Q2
$586K Buy
5,219
+5
+0.1% +$541 ﹤0.01% 1042
2018
Q1
$557K Sell
5,214
-153
-3% -$16.5K ﹤0.01% 1058
2017
Q4
$587K Buy
5,367
+1,201
+29% +$131K ﹤0.01% 1051
2017
Q3
$450K Sell
4,166
-121
-3% -$12.4K ﹤0.01% 1000
2017
Q2
$434K Sell
4,287
-642
-13% -$59.1K ﹤0.01% 1007
2017
Q1
$443K Sell
4,929
-297
-6% -$25.2K ﹤0.01% 1047
2016
Q4
$398K Buy
5,226
+857
+20% +$65.1K ﹤0.01% 1200
2016
Q3
$364K Sell
4,369
-1,100
-20% -$92.2K 0.01% 1078
2016
Q2
$451K Buy
5,469
+9
+0.2% +$741 0.01% 1019
2016
Q1
$415K Sell
5,460
-583
-10% -$43.2K 0.01% 1076
2015
Q4
$486K Buy
6,043
+561
+10% +$40.5K 0.01% 1041
2015
Q3
$348K Sell
5,482
-3,059
-36% -$220K ﹤0.01% 1082
2015
Q2
$601K Sell
8,541
-276
-3% -$20.4K 0.01% 1016
2015
Q1
$699K Sell
8,817
-1,014
-10% -$74.8K 0.01% 1023
2014
Q4
$626K Sell
9,831
-15,441
-61% -$968K 0.01% 1101
2014
Q3
$1.51M Buy
25,272
+1,716
+7% +$98.2K 0.02% 876
2014
Q2
$1.26M Buy
23,556
+17,247
+273% +$946K 0.02% 1049
2014
Q1
$381K Sell
6,309
-29,620
-82% -$1.73M ﹤0.01% 2076
2013
Q4
$1.91M Buy
35,929
+30,317
+540% +$1.52M 0.03% 755
2013
Q3
$260K Buy
+5,612
New +$258K 0.01% 1999

Other funds holding CRL

ProShare Advisors's CRL Position: Q2 2026 in Review

ProShare Advisors reduced its Charles River Laboratories (CRL) stake by 0.64% in Q2 2026, selling an estimated $8.9K and leaving 7,788 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #701.

ProShare Advisors first reported a position in CRL in Q3 2013 and has held it in 52 quarters since. The position peaked at $4.13M in Q4 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • ProShare Advisors held 7,788 shares of Charles River Laboratories worth $1.77M as of Q2 2026.
  • ProShare Advisors sold 50 Charles River Laboratories shares in Q2 2026, an estimated $8.9K.
  • Charles River Laboratories made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #701 holding.
  • ProShare Advisors first reported a position in Charles River Laboratories in Q3 2013 and has held it in 52 quarters since.
  • ProShare Advisors's Charles River Laboratories position peaked at $4.13M in Q4 2021.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.